Market Trends of Vascular Graft Industry
Kidney Failure Segment is Expected to Witness Growth Over the Forecast Period
The kidney failure segment is expected to witness the fastest growth during the forecast period owing to the increasing number of patients with kidney diseases, end-stage kidney failure, and the availability of procedures using grafts. Kidney Failure is treated by replacing a kidney through a kidney transplant. This process uses vascular grafts. The renal vessel is reconstructed in kidney transplantation using vascular grafts.
For instance, according to the article titled "Kidney Disease Statistics for the United States," published in 2021, nearly 786,000 people in the United States were living with ESRD, with 71% on dialysis and 29% with a kidney transplant. Meanwhile, the number of patients who initiated peritoneal dialysis and who received a preemptive transplant reached an all-time high of 18,631. Additionally, in 2021, a report published by the Kidney Foundation stated that around 4 million people had kidney diseases in Canada, of which 46% of new patients were under 65 years. Moreover, as per the same source, the number of people living with end-stage kidney disease has grown by 35% since 2009. Hence, owing to the rising prevalence of chronic kidney diseases, the market is expected to witness high growth over the forecast period.
Furthermore, in May 2022, the California Institute for Regenerative Medicine (CIRM) awarded UC Davis Professor Aijun Wang a USD 3 million grant to develop a smart, durable vascular device for hemodialysis patients treated for kidney failure. This device uses a unique molecule that guides the body's stem cells to help prevent the failure of synthetic vascular grafts.
Thus, the growing number of people with end-stage kidney failure is likely to increase the demand for vascular grafts, which is expected to help the market grow.
North America is Expected to Retain Largest Market Share Over the Forecast Period
North America dominates the vascular graft market. North America maintained its dominant share due to the high prevalence rates of diabetes, cardiovascular diseases, and chronic kidney diseases. The presence of reimbursement coverage and the availability of state-of-the-art healthcare infrastructure are driving the growth of this market in North America.
The major factor driving the market is the rising burden of various coronary heart diseases, such as stroke and cardiomyopathy, which cause a global burden of cardiac-related deaths. For instance, according to the May 2023 update by the Centers for Disease Control and Prevention, about 0.8 million people in the United States suffered a heart attack. Of these, 0.6 million experienced their first heart attack. Hence, the high prevalence of heart attack cases is likely to favor the utilization of vascular grafts in the country, leading to market growth over the forecast period.
Moreover, as the government ramps up investments and initiatives to advance kidney cancer therapies and diagnostics, the market is poised for growth. Notably, in November 2022, the Kidney Cancer Association (KCA) awarded two grants to researchers from the Fox Chase Cancer Center totaling USD 75,000. These grants aim to support studies that have the potential to enhance kidney cancer treatment and care.
Thus, due to the factors mentioned above, North America is expected to witness market growth over the next few years.
